Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS). It may be used alone or along with psychostimulant medication. It enhances the executive functions of…
History, Community, Culture & Applications
Explore the main themes, entities and connections around Atomoxetine. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
cyp2d6 metabolizers poor adhd extensive found may effects levels treatment exposure used 4-hydroxyatomoxetine hours increase inhibitors drug metabolism however brand
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Atomoxetine | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Atomoxetine | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Atomoxetine | ATC code | N06BA09 (WHO) | 1.00 | infobox |
| Atomoxetine | Bioavailability | 2D6Tooltip CYP2D6 EMsTooltip extensive metabolizers: 94% 2D6Tooltip CYP2D6 PMsTooltip poor metabolizers: 63% | 1.00 | infobox |
| Atomoxetine | CAS Number | 83015-26-3 Y | 1.00 | infobox |
| Atomoxetine | CAS Number | as HCl: 82248-59-7 | 1.00 | infobox |
| Atomoxetine | ChEBI | CHEBI:127342 Y | 1.00 | infobox |
| Atomoxetine | ChEBI | as HCl: CHEBI:331697 | 1.00 | infobox |
| Atomoxetine | ChEMBL | ChEMBL641 Y | 1.00 | infobox |
| Atomoxetine | ChEMBL | as HCl: ChEMBL1702 | 1.00 | infobox |
| Atomoxetine | ChemSpider | 49516 Y | 1.00 | infobox |
| Atomoxetine | ChemSpider | as HCl: 49515 | 1.00 | infobox |
| Atomoxetine | CompTox Dashboard (EPA) | DTXSID9044297 | 1.00 | infobox |
| Atomoxetine | Drug class | Norepinephrine reuptake inhibitor (NRI) | 1.00 | infobox |
| Atomoxetine | DrugBank | DB00289 Y | 1.00 | infobox |
| Atomoxetine | DrugBank | as HCl: DBSALT001207 | 1.00 | infobox |
| Atomoxetine | ECHA InfoCard | 100.120.306 | 1.00 | infobox |
| Atomoxetine | Elimination half-life | 2D6Tooltip CYP2D6 EMsTooltip extensive metabolizers: 4.5–5.3 h 2D6Tooltip CYP2D6 PMsTooltip poor metabolizers: 19–22 h | 1.00 | infobox |
| Atomoxetine | Excretion | 2D6Tooltip CYP2D6 EMsTooltip extensive metabolizers: urine (>96%), feces (1–2%) 2D6Tooltip CYP2D6 PMsTooltip poor metabolizers: urine (80%), feces (13–22%) | 1.00 | infobox |
| Atomoxetine | Formula | C17H21NO | 1.00 | infobox |
| Atomoxetine | IUPHAR/BPS | 7118 | 1.00 | infobox |
| Atomoxetine | KEGG | D07473 Y | 1.00 | infobox |
| Atomoxetine | KEGG | as HCl: D02574 | 1.00 | infobox |
| Atomoxetine | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Atomoxetine | Legal status | BR: Class C1 (Other controlled substances) | 1.00 | infobox |
| Atomoxetine | Legal status | CA: ℞-only | 1.00 | infobox |
| Atomoxetine | Legal status | NZ: Prescription only | 1.00 | infobox |
| Atomoxetine | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Atomoxetine | Legal status | US: ℞-only | 1.00 | infobox |
| Atomoxetine | Legal status | EU: Rx-only | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.